A 47-year-old man had surgery for paraaortic paraganglioma in 1980 and 1985 . In 1987 , his urinary excretion of catecholamines and metabolites was extremely high. Scintigraphy with 131I-metaiodobenzylguanidine (MIBG)showed multiple bone and liver metastases. He was treated twice with infusions of 3.7 GBqof 131I-MIBG. After the first treatment, he had transient hypertension and pain in the back and right leg. Subsequent 131I-MIBGscintigraphy showed that the number of metastatic tumors had decreased. The second treatment was less effective. Excess catecholamines were treated with alpha-methyl-p-tyrosine (MPT), a catecholamine synthesis inhibitor, at doses between 250 and 2000 mg/day, which significantly decreased urinary NE excretion. This is the first case treated with 131I-MIBG in Japan.
Themajority of pheochromocytoma cases can be cured by surgical removal of the tumor. However, therapy for metastasized malignant pheochromocytoma is difficult because the tumor is generally unresponsive to standard antitumor chemotherapy or external radiation therapy (1 ,2) . In Japan, 8.5% of pheochromocytoma cases are reported to be malignant (3) results (5-ll) . This paper reports the first case, to our knowledge, of a patient with pheochromocytoma and multiple metastases treated with 131I-MIBG and alpha-methyl-p-tyrosine (MPT), a catecholamine synthesis inhibitor.
MATERIALS AND METHODS
Scintigraphy and treatment with 131I-MIBG Epinephrine (E) and norepinephrine (NE) concentrations in plasma and urine were measured by the method described by Hansson et al (13) . Metanephrine (M) and normetanephrine (NM) were measured by radioimmunoassay (RIA) as described by Jibiki et al (14) .
CASE REPORT
A 47-year-old man had suffered headaches, palpitation, perspiration and consciousness disturbances several times a year since 1970. In 1978, he visited a hospital because of epigastralgia and was diagnosed as having multiple pancreatic cysts. In 1980, laparotomy for a possible pancreatic tumor disclosed a fist-sized tumor surrounding the abdominal aorta and inferior vena cava at the height of the renal vein. The tumor was removed. Histological examination showed the specimen to be a paraganglioma. The patient remained symptom-free until 1984, whenattacks of palpitation and headache recurred. Hypertension and high levels of plasma NEsuggested a recurrence of the paraganglioma and the patient was operated on again in May1985. A tumor behind the pancreas head was resected and no metastasis was found in 16 lymphnodes adjacent to the tumor. However, hypertension persisted and plasma NElevels gradually increased from 3.4 to 21.6 ng/ml. Scintigraphy with 131I-MIBG revealed multiple bone metastases. In February 1987, the man visited our clinic because of lumbago (numbness in the right leg) and was admitted. The patient was 173.5 cm tall and weighed 45 kg. His blood pressure was 146/95 mmHgwith orthostatic hypotension. The pulse rate was 108/min and regular. The chest was normalexcept for a systolic murmur (Levine 3-4/VI) at the left sternal border. There were several postoperative scars in the abdominal wall. The liver and spleen were not felt. Laboratory data is given Tables 1 and 2 . Plasma NE levels and urinary excretion of NEand NMincreased (Table 2) . Scintigraphy with 131I-MIBGshowed a decrease or disappearance of 131I-MIBGaccumulation in the chest (Fig. 2B ) and the pelvic area (not shown), compared to the previous scintigraphy. Pain in the hip and in the lower right leg was completely relieved and the patient was discharged.
In September 1987, he was readmitted for lumbago caused by a metastatic tumor in the hip bone. Plasma and urinary NE increased again. He received external radiation at a dose of 45 Gy (4500 rads) in the overall pelvic region and the pain subsided. He was then treated with alpha-MPT, initially at 250 mg/day, with the dose gradually increased to 2000 mg/day. There were no side effects from the alpha-MPTother than a slight weakness at the highest dose, which disappeared when the dose was lowered to 1000 mg/day. In December, the second 131I-MIBG therapy was administered. The average absorbed dose was 20 Gy/g tumor weight (0.54 Gy/MBq). The subsequent clinical course was fair;
systolic blood pressure remained below 150 mmHg and the patient had no more palpitation. (9) in cases untreatable by other techniques, in cases expected to survive at least one year without therapy, and in cases whose tumor uptake of 131I-MIBG would be sufficient to give at least 20 rads/mCi (0.54 Gy/MBq) in a lesion. Although multiple bone metastases had been reported resistant to 131I-MIBGtherapy (4), our patient responded to the first treatment with the disappearance or reduction in size of the metastatic tumor, which was associated with The drug has been widely used in Europe and the U.S. It has been reported that catecholamine secretion is decreased 25-80% within a few days of alpha-MPT at 1-4 g/day (15). In accordance with the previous report, plasma NElevels and urinary excretion of NE and NMdefinitely decreased and the blood pressure was maintained at about 130/80 mmHg,with the pulse rate at 80-90/min. There were no side effects other than a feeling of weakness at a dose of 2 g/day. In summary, a patient with malignant pheochromocytomaand multiple metastases was treated with 131I-MIBG and alpha-MPT. 131I-MIBG was partially effective in reducing tumor mass with no serious side effects. Alpha-MPTwas quite effective in controlling NE secretion and hypertension.
Further clinical study with a number of patients is necessary, however, to establish the effectiveness of 131I-MIBG therapy in malignant pheochromocytoma.
